Cardiac hypertrophy is a compensatory and adaptive response to a variety of physiological or pathological stimuli like pressure or volume stress, infarction induced loss of contractile mass and sarcomeric protein mutations (Frey et al 2004). Currently there is no specific treatment for cardiac hypertrophy which is associated with several complications including diabetes, hypertension and atherosclerosis (Goyal and Mehta 2013; Mehta 2012, Patel and Raghunathan and Patel 2013) . Hence, identification of lead targets for cardiac hypertrophy is the need of hour.
ABSTRACT
The regulatory paradigm in cardiac hypertrophy involves alterations in gene expression that is mediated by chromatin remodeling. Various data suggest that class I and class II histone deacetylases (HDACs) play opposing roles in the regulation of hypertrophic pathways. To address this, we tested the effect of magnesium valproate (MgV), an HDAC inhibitor with 5 times more potency on Class I HDAC. Cardiac hypertrophy was induced by Partial abdominal aortic constriction in wistar rats, and at end of 6 weeks, we evaluated hypertrophic, hemodynamic and oxidative stress parameters, and mitochondrial DNA concentration. Treatment with MgV prevented cardiac hypertrophy, improved hemodynamic functions, prevented oxidative stress and increased mitochondrial DNA concentration. MgV treatment also increased the survival rate of the animals as depicted by Kaplan-Meier curve.
Improvement in hypertrophy due to HDAC inhibition was further confirmed by HDAC mRNA expression studies which revealed that MgV decreases expression of pro-hypertrophic D r a f t
INTRODUCTION
Cardiac hypertrophy is a compensatory and adaptive response to a variety of physiological or pathological stimuli like pressure or volume stress, infarction induced loss of contractile mass and sarcomeric protein mutations (Frey et al 2004) . Currently there is no specific treatment for cardiac hypertrophy which is associated with several complications including diabetes, hypertension and atherosclerosis (Goyal and Mehta 2013; Mehta 2012, Patel and Raghunathan and Patel 2013) . Hence, identification of lead targets for cardiac hypertrophy is the need of hour.
The regulatory paradigm in cardiac hypertrophy involves alterations in gene expression that is mediated by chromatin remodeling. Histone acetylation and deacetylation is regulated by two sets of opposing enzymes-histone acetyltransferases (HATs) and histone deacetyalases (HDACs) respectively. HDACs, remove acetyl group from histones, resulting in its hypoacetylation which diminishes the accessibility for transcription factors to bind to DNA, leading to repression of transcription (de Ruijter et al 2003) . HDACs are composed of a highly conserved family, that fall into three subfamilies (de Ruijter et al 2003) . The Class I HDAC enzymes which are primarily located in the nucleus consist of HDAC 1, 2, 3 and 8 (Gregoretti et al 2004) . On the other contrary, class II HDAC enzymes shuttle between the cytoplasm and nucleus. Class II HDACs are further classified into class IIa (HDAc 4, 5, 7 and 9) and class IIb (HDAC 6 & 10) (de Ruijter et al 2003) . HDAC 11, which is zinc dependent, shares similarity to class I and II HDAC enzymes and hence is uncategorized (de Ruijter et al 2003) .
Various data suggest that class I and class II HDACs play opposing roles in the regulation of hypertrophic pathways. Kee et al (2006) reported predominant involvement of class I HDACs in hypertrophic response in hypertrophic animal models. Nuclear localization of class II HDACs, and thus their ability to repress Myocyte enhance factor-2 (Mef2) dependent hypertrophic gene expression, is regulated by phosphorylation of critical serine residues that D r a f t 4 are conserved in class II, but not class I, HDACs (Chang et al 2004) . Thus, class I HDAC and class II HDAC play opposing roles in regulation of cardiac hypertrophy. However, nonspecific HDAC inhibitors (HDACi) like Trichostatin A (TSA) has been found to regress hypertrophy (Kook et al 2003) . To address this, we have carried out mRNA expression studies of selected HDACs of both class I and class II HDACs in a pathological model of hypertrophy. Since there are no clinically available specific class I and class II HDAC inhibitors, we have used magnesium valproate as a model drug which is an HDACi with 5 times more sensitivity to class I HDAC (de Ruijter et al 2003) . Moreover, Magnesium valproate has been reported to exhibit beneficial effect on cardiovascular complications associated with type 2 diabetes mellitus .
METHODS
The protocol of the experiment was approved by our institutional animal ethics committee as (by converting human dose to animal dose). The treatment was given in group 3 and 4 for 6 weeks during which body weight changes and mortality rate was monitored.
Blood Sample Collection and Serum Analysis
At the end of five weeks, blood samples were collected from the retro orbital plexuses of each rat under light ether anesthesia. Serum was separated and were analyzed for triglycerides, total cholesterol, very low density lipoprotein (VLDL), low density lipoprotein
administered by i.m. route, individually. The optimum body temperature of 37 ± 1 °C was maintained throughout the measurement. The upper abdomen was opened and trachea was located and the carotid artery behind it was cannulated. The hemodynamics were measure using BP 100 transducer (Labscrib Systems, IWORX, New Hampshire, USA). All the data were analyzed using Labscribe software (Version 118) ).
Measurement of Hypertrophic Parameters
Once the hemodynamics were measure in the rats, they were euthanized by using an overdose of ketamine (80mg/kg IM). The hearts were removed and other extraneous tissues were discarded. The wet weight of entire heart, left ventricle and right ventricle were recorded and femur length was noted down to calculate various hypertrophic indices like cardiac hypertrophic index (CHI) and left ventricular (LV) hypertrophy index (LVHI) as per previously reported method (Goyal et al. 2011, Patel and . Using screw gauge micrometer LV wall thickness was also noted down (Rayabarapu and Patel 2014 ).
Oxidative stress measurement
Oxidative stress levels were measured in the left ventricular tissue of heart samples by preparing homogenate of left ventricle (Goyal and Mehta 2012; ).
Quantification of tissue protein levels (Lowry et al. 1951) , malondialdehyde levels (MDA) (Ohkawa et al. 1979) , reduced gluatathione levels (GSH) (Beutler et al. 1963 ) and superoxide dismutase levels (SOD) (Misra and Frodvich 1972) was performed.
Mitochondrial DNA isolation and quantification
hearts in each treatment were studied under OLYMPUS (trinocular-CX21FS1) microscope with 100 X and 400 X magnifications for examination of overall morphology of left ventricle and cell diameter measurements were taken with Image J analyzer software (NIH) 1.45.
mRNA Expression Studies
Total ribonucleic acid (RNA) was extracted from intact hearts using the FastRNA® Pro
Green Kit (MPBIO) according to the manufacturer's instructions. The reverse transcription (RT) reaction was performed using First Strand cDNA Synthesis kit (Novagen). Real-time polymerase chain reaction (PCR) was performed in LightCycler® 480 (Roche Applied Biosciences) using TaqMan Universal PCR Master mix for determining mRNA levels of histone deacetylase 2 (HDAC2) and histone deacetylase 5 (HDAC5). To detect HDAC 2 and HDAC 5, specific primers were designed with the 'Primer 3Plus' Program listed in table 1.
All reactions were performed in duplicate. The PCR product was separated using electrophoresis on 1% agarose gel and semi-quantified as a ratio to GAPDH.
Statistical Analysis:
All the values were expressed as mean ± S.E.M. Statistical analysis between normal control and disease control groups and between disease control and disease treated group were performed using one-way ANOVA followed by Tukey's posttest, using Prism 5.01
(GraphPad Software). Differences were considered to be statistically significant when p < 0.05.
RESULTS

HYPERTROPHIC PARAMETERS
PAAC model is a representative of pathological cardiac hypertrophic condition. To determine if PAAC induced cardiac hypertrophy could be treated with HDAC inhibition, we treated rats with magnesium valproate. It was observed that cardiac hypertrophic index (CHI), LV hypertrophy index (LVHI) was significantly higher in hypertrophic rats as compared to D r a f t 8 control rats. Treatment with magnesium valproate significantly reduced the elevated CHI and LVHI of hypertrophic rats ( Figure 1A , 1B). Further, HW/BW and LVW/RVW were increased significantly in hypertrophic rats as compared to those of control rats. Magnesium valproate administration significantly reduced the increase in HW/BW and LVW/RVW of hypertrophic rats ( Figure 1C, 1D ). This was further confirmed by changes in LV wall thickness, cardiomyocyte diameter and LV collagen levels which was reduced by magnesium valproate treatment (Figure 2A , 2B, 2C).
HEMODYNAMIC PARAMETERS
In the earlier stage, hypertrophized ventricle is able to compensate for increased work load, but eventually in the later stages, impairment of diastolic function followed by systolic function is observed, resulting in decompensation and heart failure (Raghunathan and Patel 2013 ). Thus we evaluated the ventricular performance by invasive hemodynamic pressure recording and assessed the impact of HDACi magnesium valproate in cardiac functioning. As expected, there was a significant increase in the MABP and heart rate in PAAC hypertrophic rats as compared to control rats. Treatment with magnesium valproate significantly prevented the increase in MABP and attenuated increased heat rate in hypertrophic rats (Table 2) .
Further, the hypertrophic rats also exhibited a significantly decreased rate of pressure development (dp/dt max) and decay (dp/dt min) as compared to control rats which was significantly increased by magnesium valproate treatment (Table 2) .
SERUM LIPID PROFILE
Dyslipidaemia is one of the most modifiable risk factors for CVDs. PAAC is a model of pathological hypertrophy and is associated with decreased fatty acid oxidation (DavilaRoman et al. 2002) . PAAC hypertrophic rats exhibited significantly increase in serum total cholesterol, LDL, VLDL and triglyceride levels and log TG/HDL ratio and decrease in serum HLD levels as compared to control rats. Treatment with magnesium valproate showed significant improvement in lipid profiles (Table 2) . D r a f t
NON-SPECIFIC SERUM CARDIAC MARKERS
Concentrations of CK-MB have been found to be significantly higher in human myocardium with coronary artery disease, aortic stenosis, or heart failure (Hakan et al. 2002) . A significant increased level of LDH is found in case of myocardial damage due to hypertrophy. CRP is a sensitive, nonspecific systemic marker of inflammation and its elevated levels are associated with traditional cardiovascular risk factors. Na-K-ATPase dysfunctioning has been found to be associated with myocardial contractile dysfunction. Hence, in present study, we have measured serum CK-MB, LDH and CRP levels as LV Na+ K+ ATPase activity. PAAC rats produced significant increase in serum LDH, CK-MB and CRP levels and reduction in LV Na + K + ATPase activity as compared to control rats. Treatment with magnesium valproate showed significant reduction in LDH, CK-MB and CRP levels and increase in Na + K + ATPase activity (Table 3) .
OXIDATIVE STRESS PARAMETERS
Reactive oxygen species (ROS) aggravates cardiac hypertrophy in pressure overload induced cardiac hypertrophy with progression to heart failure (Han et al. 2009 ) and hence, measurement of pro-oxidants and anti-oxidant levels is suggestive of cardiac damage. In present investigation, hypertrophic control rats showed a significantly increase in LV MDA levels and significantly decreased LV SOD and GSH levels as compared to control rats. concentration as compared to control rats. Treatment with magnesium valporate significantly increased the reduced mtDNA concentration in hypertrophic treated rats as compared to hypertrophic control rats ( Figure 3A ).
KAPLAN-MEIER PLOT FOR SURVIVAL PROBABILITY
It is important to evaluate the long term efficacy and tolerability of magnesium valproate in clinical use. In lieu of this we monitored the animals for 6 weeks and plotted the KaplanMeier curve. Kaplan-Meier analysis revealed that the survival rate was 50% at 35 days after surgery. However, administration of magnesium valproate improved the survival rate to 80%
in PAAC model ( Figure 3B ).
HISTOPATHOLOGICAL ANALYSIS
Histopathological examination of longitudinal section of left ventricle (100X) in control and control treated with magnesium valproate rats showed normal long parallel cardiac fibres with normal interstitial space ( Figure 4A, 4B) . On the contrary, hypertrophic control rats revealed irregular cardiac fibres, reduction in interstitial space and fibrosis ( Figure 4C, 4D) (100X).
Further, the histopathological analysis at 400X showed no signs of injury in control and control treated with magnesium valproate (210 mg/kg/day, p.o.) ( Figure 4E, 4F) . However, hypertrophic control sections at 400X exhibited increased fibroblast, apoptotic cardiomyocyte, increased eosinophilia and extravasated RBCs ( Figure 4G , 4H, 4I) as compared to control animals. Treatment with magnesium valproate in hypertrophic treated rats prevented the signs of hypertrophic damage to cardiomyocytes ( Figure 4J ). HDAC enzyme and HDAC5, a class II HDAC mRNA levels were measured in the heart in present study.
Hypertrophic control rats exhibited a significant relative fold increase in HDAC 2 and HDAC 5 mRNA levels as compared to control rats. Treatment with magnesium valproate (210 mg/kg/day, p.o.) significantly reduced the expression of HDAC 2 in hypertrophic rats as compared to control rats. However, administration of magnesium valproate in hypertrophic rats did not produce any significant change in HDAC 5 mRNA levels as compared to control rats ( Figure 5A , 5B).
DISCUSSION
Results of the present investigation provide sufficient evidence that magnesium valproate prevents cardiac hypertrophy induced by PAAC, through inhibition of HDAC2. In the present investigation, HDAC2 and HDAC5 mRNA level were significantly increased in hypertrophic rats as compared to control rats. Chronic treatment with magnesium valproate significantly reduced the HDAC2 mRNA level, but had no significant effect on HDAC5 mRNA level. 2) Catalytic activity is not essential for class IIa HDACs to suppress hypertrophic signalling in cardiomyocytes (Zhang et al. 2002) .
3) Enzymatic assays have revealed the insensitivity of standard HDACi (including those used in cardiac hypertophic studies till date) for class IIa HDACs (Bradner et al. 2010) .
In the present study, magnesium valproate reduced hypertrophic indices and collagen levels in the treated rats. It has been reported that Hsp70-Hsp90 (Hop), heart enriched nuclear factor, is a cardiac specific regulator of gene transcription and generates hypertrophy by Magnesium valproate also significantly improved the hemodynamics by reducing blood pressure, heart rate and improving left ventricular functioning. It is reported that Inpp5f suppression due to HDAC2 overexpression activates the phosphatidylinositol 3-kinase (PI3K) Akt-Gsk3β pathway, thus producing cardiac hypertrophy (Trivedi et al. 2007 ). This D r a f t 13 supports the possibility that improved hemodynamics and contractility by magnesium valproate in current study may be due to the modulation of (PI3K-) Akt-Gsk3β pathway by HDAC2 inhibition, which is a negative regulator of cardiac contractility.
In the present investigation, PAAC control rats exhibited significant dyslipidaemia. Chronic treatment with magnesium valproate significantly improved the lipid profile. It is reported that trichostatin A (TSA) treatment in F9 EC cells downregulated the expression levels of 9 out of 15 enzymes involved in cholesterol biosynthesis, including HMG CoA reductase, mevlonate kinase and others (Chittur et al. 2008 The results of present study suggest that there was a significant increase in serum CK-MB, CRP and LDH levels along with significant reduction of Na leads to disruption of mitochondrial proteins and mtDNA mutation (Bugger and Abel 2010) .
It has been suggested that lack of complex chromatin organization consisting of histone proteins, limited the reparative ability of mtDNA and impermeability of internally formed O 2-in mitochondria, may be the possible reasons for ROS mediated mtDNA damage (Ide et al. 2001 ). It has been reported that owing to its HDACi activity, phenylbutyrate might have increased MnSOD levels against adriamycin toxicity in a mouse model (Daosukho et al. 2007) . It has been shown that localized deacetylation of H3 and H4 in MnSOD gene's proximal promoter region which is executed by HDAC1, was reversed by class I specific HDACi-trichostatin A (Maehara et al. 2002) . In another study, HDACi by valproic acid attenuated the increased ROS in spontaneously hypertensive rats (Cardinale et al. 2010) .
Thus, magnesium valproate, through its HDACi activity prevented oxidative stress and i.e. their major action on class I over class II HDAC. This would ensure curbing the disease at core, eliminating side-effects and associated complications, which are major drawback for existing therapies.
CONCLUSION
In conclusion, this study gives an insight that selective class I HDACi are required for controlling cardiac hypertrophy. Till date, the HDACi used are non-selective, differing in terms of relative selectivity. Hence, this study is one of its kind suggesting that modifying the structure of magnesium valproate to obtain still more selectivity towards class I HDAC should be a strategy. Furthermore, newer HDAC inhibitors which are class I inhibitor and class II promoter can be designed to obtain a 'pan' or 'dual' natural HDAC 'regulators'. D r a f t D r a f t Goyal, B.R., and Mehta, A.A. 2012 . 
